drugset / Trial / NCT00196846

Prevention of Chemotherapy Induced Ovarian Failure With Goserelin in BC Patients (ZORO)

NCT00196846

Phase 2 Completed 62 enrolled GBG Forschungs GmbH
RandomizedParallel-groupOpen-labelPrevention

Summary

Study done in young breast cancer patients to prevent chemotherapy induced ovarian failure

Timeline

Start
2005-03
Primary completion
2008-12
Completion
2010-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Goserelin Other / unclassified 3.6 mg Subcutaneous

Indications